Read More Pharma Industry News VYNE Therapeutics and Yarrow Bioscience merger signals strategic reset toward autoimmune thyroid therapeutics Find out how VYNE Therapeutics’ merger with Yarrow Bioscience resets its strategy around a $200M-backed autoimmune thyroid disease pipeline. bySoujanya RaviDecember 17, 2025